~~<i id='2497F4DCB5'><strike id='2497F4DCB5'><tt id='2497F4DCB5'><pre id='2497F4DCB5'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：leisure time 2025-10-02 09:35:25 Page View：3458

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Zyn nicotine pouches become unlikely player in latest culture war
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

explore

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

FDA panel to weigh safety of artificial wombs for preterm births

AdobeTheartificialwomb,adeviceaimingtosaveinfantsbornwaytoosoon,isinchingclosertobeingtestedinhumans

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Philips to halt sales of sleep apnea machines in U.S.

SEMVANDERWAL/ANP/AFPviaGettyImagesWASHINGTON(AP)—Thecompanybehindaglobalrecallofsleepapneamachinessa